, a radiology artificial intelligence (AI) company with a growing presence in the Asia-Pacific, Europe, and the United Kingdom, has announced the appointment of healthcare technology executives Lakshmi Gudapakkam as CEO and clinical strategist Rick Abramson, MHCDS, FACR, as chief medical officer. With the new appointments, expects to further accelerate its global market presence and entry into the U.S. market, following recent FDA approvals for part of its comprehensive radiology AI product. combines AI with clinical expertise to bring comprehensive AI products to market quickly, with advanced performance and a focus on clinical success. Formed in 2019 as a joint venture between healthcare AI platform and I-MED Radiology Network, Australia’s largest diagnostic imaging network, the company is focused on rapidly developing and commercialising comprehensive AI products to advance patient care. products have been used to help more than 1 million patients since launch. Annalise Enterprise CXR, the comprehensive decision-support AI solution for chest X-rays, is already in clinical use at over 400 sites in Australia and the UK and accessible by one in four Australian radiologists. A recent peer-reviewed diagnostic accuracy study published in The Lancet Digital Health found Annalise Enterprise CXR improved radiologists’ diagnostic accuracy across 102 chest X-ray (CXR) findings*.

The company has clearance for clinical use for Annalise Enterprise CXR in Australia, the United Kingdom, Europe, Southeast Asia, and New Zealand, and is expanding its products to new geographies. Earlier this year, Annalise Enterprise CXR received CADt FDA clearance for use in triage and notification of pneumothorax and tension pneumothorax on chest X-rays.

The appointment of Gudapakkam as CEO will help accelerate expansion plans globally and into the US along with the development of new AI radiology tools. Gudapakkam brings a wealth of health-tech expertise, serving in senior global technology and business leadership roles for more than 20 years in GE Healthcare and Philips Healthcare and for the last four years with Quest Diagnostics, as their Vice President and General Manager for their East Region.

During his time with GE Healthcare, Gudapakkam led large global teams across U.S., Canada, Europe, India, China, and Australia in large, breakthrough product development for radiology imaging, cardiology imaging and healthcare informatics.

At Philips Healthcare, he oversaw breakthrough products in CT and advanced visualization imaging. Later, Gudapakkam moved into global business leadership roles, building up the Philips Healthcare footprint across China, India, and the rest of Asia. He Gudapakkam led large global businesses including the Global Value Segment business, Global X-ray & Mammography business and later a portfolio of global businesses including CT, Molecular Imaging, x-ray and Mammography.

During his time at Quest Diagnostics, Gudapakkam oversaw expansion of the company’s diagnostic services through lab management partnerships, managing the scaling of the testing through the COVID pandemic period while leading major transformational programs including standardizing IT systems and building out a mega lab in Clifton, N.J., and consolidating lab testing in the East region.

Across his career, Gudapakkam has dealt closely with both technologists and clinical experts in radiology and imaging, providing a broad network and the perfect mix of skills and business acumen to help translate complex technologies into specialist healthcare.

Strengthening its global leadership bench even further, Rick Abramson, MD, MHCDS, FACR, joins the team as CMO and will be responsible for guiding the company’s clinical roadmap for international expansion. A U.S.-based physician leader and board-certified radiologist, Abramson brings more than 25 years of experience in healthcare including prior roles in clinical practice, academic research, policy development, and management. Previously corporate vice-president over the radiology service line at HCA Healthcare, Inc., Abramson led enterprise strategic development for radiology and artificial intelligence across HCA’s network of 185 hospitals in the US and the UK.

In his new role with, Abramson will help advance stakeholder partnerships with healthcare providers, technology developers, and regulatory bodies across the world.

Having played an integral role in the formation and success of the joint venture, Founding CEO Dimitry Tran will continue to serve as Director of the Board and part of the team. Dr Aengus Tran, Co-Founder and CEO of, will also continue as’s Chief AI Officer.